Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

B. Rossetti, R. Gagliardini, G. Meini, G. Sterrantino, V. Colangeli, M.C. Re, A. Latini, M. Colafigli, F. Vignale, S. Rusconi, V. Micheli, A.D. Biagio, G. Orofino, V. Ghisetti, A. Fantauzzi, V. Vullo, P. Grima, D. Francisci, C. Mastroianni, A. Antinori & 10 others M. Trezzi, L. Lisi, P. Navarra, B. Canovari, A. D’Arminio Monforte, S. Lamonica, A. D’Avino, M. Zazzi, S.D. Giambenedetto, A. De Luca

Research output: Contribution to journalArticle

6 Citations (Scopus)
Original languageEnglish
Article numbere0187393
Number of pages18
JournalPLoS One
Volume12
Issue number11
DOIs
Publication statusPublished - Nov 21 2017

Cite this

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial. / Rossetti, B.; Gagliardini, R.; Meini, G.; Sterrantino, G.; Colangeli, V.; Re, M.C.; Latini, A.; Colafigli, M.; Vignale, F.; Rusconi, S.; Micheli, V.; Biagio, A.D.; Orofino, G.; Ghisetti, V.; Fantauzzi, A.; Vullo, V.; Grima, P.; Francisci, D.; Mastroianni, C.; Antinori, A.; Trezzi, M.; Lisi, L.; Navarra, P.; Canovari, B.; D’Arminio Monforte, A.; Lamonica, S.; D’Avino, A.; Zazzi, M.; Giambenedetto, S.D.; De Luca, A.

In: PLoS One, Vol. 12, No. 11, e0187393, 21.11.2017.

Research output: Contribution to journalArticle

Rossetti, B, Gagliardini, R, Meini, G, Sterrantino, G, Colangeli, V, Re, MC, Latini, A, Colafigli, M, Vignale, F, Rusconi, S, Micheli, V, Biagio, AD, Orofino, G, Ghisetti, V, Fantauzzi, A, Vullo, V, Grima, P, Francisci, D, Mastroianni, C, Antinori, A, Trezzi, M, Lisi, L, Navarra, P, Canovari, B, D’Arminio Monforte, A, Lamonica, S, D’Avino, A, Zazzi, M, Giambenedetto, SD & De Luca, A 2017, 'Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial', PLoS One, vol. 12, no. 11, e0187393. https://doi.org/10.1371/journal.pone.0187393
Rossetti, B. ; Gagliardini, R. ; Meini, G. ; Sterrantino, G. ; Colangeli, V. ; Re, M.C. ; Latini, A. ; Colafigli, M. ; Vignale, F. ; Rusconi, S. ; Micheli, V. ; Biagio, A.D. ; Orofino, G. ; Ghisetti, V. ; Fantauzzi, A. ; Vullo, V. ; Grima, P. ; Francisci, D. ; Mastroianni, C. ; Antinori, A. ; Trezzi, M. ; Lisi, L. ; Navarra, P. ; Canovari, B. ; D’Arminio Monforte, A. ; Lamonica, S. ; D’Avino, A. ; Zazzi, M. ; Giambenedetto, S.D. ; De Luca, A. / Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial. In: PLoS One. 2017 ; Vol. 12, No. 11.
@article{8deb7c5dc1dd49d7a1414bc3263685e0,
title = "Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial",
author = "B. Rossetti and R. Gagliardini and G. Meini and G. Sterrantino and V. Colangeli and M.C. Re and A. Latini and M. Colafigli and F. Vignale and S. Rusconi and V. Micheli and A.D. Biagio and G. Orofino and V. Ghisetti and A. Fantauzzi and V. Vullo and P. Grima and D. Francisci and C. Mastroianni and A. Antinori and M. Trezzi and L. Lisi and P. Navarra and B. Canovari and {D’Arminio Monforte}, A. and S. Lamonica and A. D’Avino and M. Zazzi and S.D. Giambenedetto and {De Luca}, A.",
note = "cited By 0",
year = "2017",
month = "11",
day = "21",
doi = "10.1371/journal.pone.0187393",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

AU - Rossetti, B.

AU - Gagliardini, R.

AU - Meini, G.

AU - Sterrantino, G.

AU - Colangeli, V.

AU - Re, M.C.

AU - Latini, A.

AU - Colafigli, M.

AU - Vignale, F.

AU - Rusconi, S.

AU - Micheli, V.

AU - Biagio, A.D.

AU - Orofino, G.

AU - Ghisetti, V.

AU - Fantauzzi, A.

AU - Vullo, V.

AU - Grima, P.

AU - Francisci, D.

AU - Mastroianni, C.

AU - Antinori, A.

AU - Trezzi, M.

AU - Lisi, L.

AU - Navarra, P.

AU - Canovari, B.

AU - D’Arminio Monforte, A.

AU - Lamonica, S.

AU - D’Avino, A.

AU - Zazzi, M.

AU - Giambenedetto, S.D.

AU - De Luca, A.

N1 - cited By 0

PY - 2017/11/21

Y1 - 2017/11/21

U2 - 10.1371/journal.pone.0187393

DO - 10.1371/journal.pone.0187393

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e0187393

ER -